2653 protocols found
Protocols under revision.
Abemaciclib 150 / Anastrozole 1, Breast Cancer (PID567)
Abemaciclib 150 / Anastrozole 1, Breast Cancer, adjuvant (PID1785)
Abemaciclib 150 / Fulvestrant 500, Breast Cancer, Cycle 1 (PID1408)
Abemaciclib 150 / Fulvestrant 500, Breast Cancer, Cycle 2+ (PID1409)
Abemaciclib 150 / Letrozole 2.5, Breast Cancer (PID566)
Abemaciclib 150 / Letrozole 2.5, Breast Cancer, Adjuvant (PID1786)
Abiraterone 1000 / Dexamethasone 0.5, Prostate Cancer Castration Resistant (PID2311)
Abiraterone 1000 / Prednisolone 5 / Goserelin 10.8, Prostate Cancer, First Line (PID1002)
Abiraterone 1000 / Prednisolone 5, Prostate Cancer Hormone Sensitive (PID1504)
Abiraterone 1000 / Prednisolone 5, Prostate Cancer, First Line (PID919)
Abiraterone 1000 / Prednisolone 5, Prostate Cancer, Second Line (PID920)
ABVD - Doxorubicin 25 / Bleomycin 10 / Vinblastine 6 / Dacarbazine 375, Hodgkin Lymphoma (PID472)
Acalabrutinib 100 / Obinutuzumab (100/900/1000), Chronic Lymphocytic Leukemia, Cycle 2 (PID1655)
Acalabrutinib 100 / Obinutuzumab (100/900/1000), Chronic Lymphocytic Leukemia, Cycle 2, Variant 1. (PID2283)
Acalabrutinib 100 / Obinutuzumab 1000 / Venetoclax (20/50/100/200/400), Chronic Lymphocytic Leukemia, Cycle 4. (PID2285)
Acalabrutinib 100 / Obinutuzumab 1000 / Venetoclax 400, Chronic Lymphocytic Leukemia, cycle 5-7. (PID2286)
Acalabrutinib 100 / Obinutuzumab 1000, Chronic Lymphocytic Leukemia, Cycle 3, Variant 1 (PID2284)
Acalabrutinib 100 / Obinutuzumab 1000, Chronic Lymphocytic Leukemia, Cycle 3-7 (PID1656)
Acalabrutinib 100 / Venetoclax 400, Chronic Lymphocytic Leukemia, Cycle 8+ (PID2287)
Acalabrutinib 100, Chronic Lymphocytic Leukemia (PID1653)
Acalabrutinib 100, Chronic Lymphocytic Leukemia, second line (PID1657)
Acalabrutinib 100, Chronic Lymphocytic Leukemia, Cycle 1 (PID1654)
Acalabrutinib 100, Chronic Lymphocytic Leukemia, Cycle 1, Variant 1 (PID2282)
Acalabrutinib 100, Marginal Zone Lymphoma (PID2402)
ACO II - Doxorubicin 60 / Cyclophosphamide 750 / Vincristine 1.5, Small Cell Lung Carcinoma (PID218)
Adagrasib 600 / Cetuximab 250, Colorectal Carcinoma, Cycle 2+ (PID2549)
Adagrasib 600 / Cetuximab 400, Colorectal Carcinoma, Cycle 1 (PID2548)
Adagrasib 600 / Cetuximab 500, Colorectal Carcinoma, Variant 1, Cycle 2+ (PID2602)
Adagrasib 600, Non-Small Cell Lung Cancer (PID2547)
Adagrasib 600, Tumor Biomarker Defined (PID2668)
ADOC - Cisplatin 50 / Doxorubicin 40 / Vincristine 0.6 / Cyclophosphamide 700, Thymoma (PID369)
Afatinib 40, Non-Small Cell Lung Cancer (Squamous) (PID735)
Afatinib 40, Non-Small Cell Lung Carcinoma, Adeno- (PID197)
AIO (Folinic Acid 500 / Fluorouracil 2000) / Irinotecan 80, Colorectal Carcinoma (PID467)
AIO (Folinic Acid 500 / Fluorouracil 2600) / Bevacizumab 5, Colorectal Carcinoma (PID468)
AIO (Folinic Acid 500 / Fluorouracil 2600), Colorectal Carcinoma (PID39)
AIO - Folinic Acid 500 / Fluorouracil 1500 / Irinotecan 80 / Cetuximab (400/250), Colorectal Carcinoma, Cycle 1 (PID485)
AIO - Folinic Acid 500 / Fluorouracil 1500 / Irinotecan 80 / Cetuximab 250, Colorectal Carcinoma, Cycle 2+ (PID486)
Alectinib 300, diffuse large B-non-Hodgkin Lymphoma (PID2404)
Alectinib 600, Non-Small Cell Lung Cancer (ALK+), First-Line (PID975)
Alectinib 600, Non-Small Cell Lung Cancer (ALK+), Second Line (PID888)
Alectinib 600, Non-Small Cell Lung Cancer, adjuvant (PID2614)
Alemtuzumab (3/10/30), T-Cell Prolymphocyte Leukemia, Cycle 1 (PID1548)
Alemtuzumab 3/10/30, Chronic Lymphocytic Leukemia (PID333)
Alemtuzumab 30, Chronic Lymphocytic Leukemia (PID334)
Alemtuzumab 30, T-prolymphocytic leukemia, cycle 2+ (PID1549)
Alpelisib 300 / Fulvestrant 500, Breast Cancer, Cycle 1 (PID1620)
Alpelisib 300 / Fulvestrant 500, Breast Cancer, Cycle 2+ (PID1621)
Amivantamab (350/1050/1400), Non-Small Cell Lung Cancer, cycle 1 (PID1912)
Amivantamab (350/700/1050), Non-Small Cell Lung Cancer, Cycle 1 (PID1908)
Amivantamab 1050, Non-Small Cell Lung Cancer, cycle 2+ (PID1909)
Amivantamab 1400, Non-Small Cell Lung Cancer, cycle 2+ (PID1913)
Anagrelide 0.5, Essential Thrombocythemia (PID1218)
Anakinra 1, Macrophage activation syndrome in Hemophagocytic Lymphohistiocytosis (PID649)
Anastrozole 1 / Fulvestrant 500, Breast Cancer (PID1248)
Anastrozole 1 / Breast Cancer (PID1233)
Anastrozole 1, Endometrial Cancer (PID2199)
Anastrozole 1, Breast Carcinoma, adjuvant (PID1581)
Anti-thymocyte Globulin (Rabbit) 3.5 / Ciclosporin 5 / Eltrombopag 150, Severe Aplastic Anemia (PID2716)
Anti-thymocyte Globulin (Rabbit) 3.5 / Ciclosporin 5, Severe Aplastic Anemia (PID2715)
Anti-thymocyte Globulin (Equine) 15 / Ciclosporin 5, Myelodysplastic Syndrome. (PID1766)
Anti-thymocyte globulin (Equine) 40 / Ciclosporin 5 / Eltrombopag 150, Severe Aplastic Anemia (PID1779)
Anti-thymocyte Globulin (Equine) 40 / Ciclosporin 5, Severe Aplastic Anemia (PID908)
Apalutamide 240, Prostate Cancer hormone sensitive (PID1503)
Apalutamide 240, Prostate Cancer Castration Resistant (PID1232)
APL2006 V4.1 - A1 - Idarubicin 12 / Cytarabine 200, 1st consolidation, Acute Promyelocytic Leukemia, up to 70 years, leukocytes up to 10000/µl (PID1042)
APL2006 V4.1 - A1 - Idarubicin 9 / Cytarabine 1000, 2nd consolidation, Acute Promyelocytic Leukemia, up to 70 years, leukocytes up to 10000/µl (PID1043)
APL2006 V4.1 - A1, A2 and A3, Tretinoin 45 / Idarubicin 12 / Cytarabine 200, induction, Acute Promyelocytic Leukemia, up to 70 years, leukocytes up to 10000/µl (PID1035)
APL2006 V4.1 - A1, A2, A3, C1, and C2 - Mercaptopurine 90 / Methotrexate 15 / Tretinoin 45, maintenance, Acute Promyelocytic Leukemia, up to 70 years of age (PID1053)
APL2006 V4.1 - A2 - Idarubicin 12 / Arsenic Trioxide 0.15, 1st consolidation, Acute Promyelocytic Leukemia, up to 70 years, leukocytes up to 10000/µl (PID1044)
APL2006 V4.1 - A2 - Idarubicin 9 / Arsenic Trioxide 0.15, 2nd consolidation, Acute Promyelocytic Leukemia, up to 70 years, leukocytes up to 10000/µl (PID1045)
APL2006 V4.1 - A3 - Tretinoin 45 / Idarubicin 12, 1st consolidation, Acute Promyelocytic Leukemia, up to 70 years, leukocytes up to 10000/µl (PID1046)
APL2006 V4.1 - A3 - Tretinoin 45 / Idarubicin 12, 2nd consolidation, Acute Promyelocytic Leukemia, up to 70 years, leukocytes up to 10000/µl (PID1047)
APL2006 V4.1 - B - Idarubicin 9 / Arsenic Trioxide 0.15, 1st consolidation, Acute Promyelocytic Leukemia, older than 70 years, leukocytes up to 10000/µl (PID1055)
APL2006 V4.1 - B - Tretinoin 45 / Arsenic Trioxide 0.15, 2nd consolidation, Acute Promyelocytic Leukemia, older than 70 years of age, leukocytes up to 10000/µl (PID1056)
APL2006 V4.1 - B - Tretinoin 45 / Idarubicin 9, induction, Acute Promyelocytic Leukemia, older than 70 years, leukocytes up to 10000/µl (PID1054)
APL2006 V4.1 - B and D, Arsenic Trioxide 0.15, maintenance, Acute Promyelocytic Leukemia, older than 70 years, cycle 2-5 (PID1058)
APL2006 V4.1 - B and D, Mercaptopurine 90 / Methotrexate 150 / Tretinoin 45, maintenance, Acute Promyelocytic Leukemia, older than 70 years, cycle 1 (PID1057)
APL2006 V4.1 - B and D, Mercaptopurine 90 / Methotrexate 150 / Tretinoin 45, maintenance, Acute Promyelocytic Leukemia, older than 70 years, cycle 6-8 (PID1062)
APL2006 V4.1 - C1 - Idarubicin 12 / Cytarabine 200, 1st consolidation, Acute Promyelocytic Leukemia, up to 70, leukoc. over 10000/µl (PID1049)
APL2006 V4.1 - C1 - Idarubicin 9 / Cytarabine 1000, 2nd consolidation, Acute Promyelocytic Leukemia, up to 70 years, leukocytes over 10000/µl (PID1050)
APL2006 V4.1 - C1 and C2, Tretinoin 45 / Idarubicin 12 / Cytarabine 200, induction, Acute Promyelocytic Leukemia, up to 70 years, leukocytes over 10000/µl (PID1048)
APL2006 V4.1 - C2 - Idarubicin 12 / Arsenic Trioxide 0.15, 1st consolidation, Acute Promyelocytic Leukemia, up to 70 years, leukocytes over 10000/µl (PID1051)
APL2006 V4.1 - C2 - Idarubicin 9 / Arsenic Trioxide 0.15, 2nd consolidation, Acute Promyelocytic Leukemia, up to 70 years, leukocytes over 10000/µl (PID1052)
APL2006 V4.1 - D - Idarubicin 9 / Arsenic Trioxide 0.15, 1st consolidation, Acute Promyelocytic Leukemia, over 70 years, leukocytes over 10000/µl (PID1060)
APL2006 V4.1 - D - Tretinoin 45 / Arsenic Trioxide 0.15, 2nd consolidation, Acute Promyelocytic Leukemia, over 70 years, leukocytes over 10000/µl (PID1061)
APL2006 V4.1 - D - Tretinoin 45 / Idarubicin 9 / Cytarabine 120, induction, Acute Promyelocytic Leukemia, over 70 years, leukocytes over 10000/µl (PID1059)
Asciminib 40, Chronic Myeloid Leukemia (PID2144)
Atezolimab 1200 / Carboplatin 5 / Etoposide 100, Small Cell Lung Cancer (PID1341)
Atezolizumab 1200 / Bevacizumab 15, Hepatocellular Carcinoma (PID1537)
Atezolizumab 1200 / Bevacizumab 15, Renal Cell Carcinoma (PID1604)
Atezolizumab 1200 / Bevacizumab 15, peritoneal mesothelioma (PID1934)
Atezolizumab 1200 / Bevazicumab 15 / Paclitaxel 175 / Carboplatin 5, Non-Small Cell Lung Cancer (PID2525)
Atezolizumab 1200 / Bevazicumab 15 / Paclitaxel 175 / Carboplatin 5, Cervical Cancer (PID2657)
Atezolizumab 1200 / Bevazicumab 15 / Paclitaxel 175 / Cisplatin 50, Cervical Cancer (PID2658)
Atezolizumab 1200 / Bevazicumab 15 / Paclitaxel 200 / Carboplatin 6, Non-Small Cell Lung Cancer (PID1208)
Atezolizumab 1200 / Bevazicumab 15, Maintenance, Non-Small Cell Lung Cancer (PID1209)
Atezolizumab 1200 / Bevazicumab 15, Cervical Cancer, maintenance (PID2659)
Atezolizumab 1200 / Cabozantinib 40, Renal Cell Carcinoma (PID1957)
Atezolizumab 1200 / Carboplatin 6 / Nab-Paclitaxel 100 - Atezolizumab 1200 Maintenance, Non-Small Cell Lung Carcinoma (PID1272)
Atezolizumab 1200 / Carboplatin 6 / Nab-Paclitaxel 100, Non-Small Cell Lung Cancer (PID1238)
Atezolizumab 1200 / Paclitaxel 175 / Carboplatin 5 - Atezolizumab 1200, Endometrial Cancer, Cycle 9+ (PID2699)
Atezolizumab 1200 / Paclitaxel 175 / Carboplatin 5, Endometrial Cancer, Cycle 1-8 (PID2698)
Atezolizumab 1200, Bladder Cancer, first line (PID1034)
Atezolizumab 1200, Bladder Cancer, Second Line (PID1026)
Atezolizumab 1200, Lung Carcinoma, Small Cell, Maintenance (PID1342)
Atezolizumab 1200, Breast Cancer, adjuvant (PID2425)
Atezolizumab 1200, Non-Small Cell Lung Cancer, adjuvant (PID2252)
Atezolizumab 1200, Non-Small Cell Lung Cancer, First-Line (PID1690)
Atezolizumab 1200, Non-Small Cell Lung Cancer, Second Line (PID886)
Atezolizumab 1200, Soft Tissue Sarcoma (PID2455)
Atezolizumab 1680, Bladder Cancer, First Line (PID1659)
Atezolizumab 1680, Bladder Cancer, Second Line (PID1661)
Atezolizumab 1680, Non-Small Cell Lung Cancer, Second Line (PID1663)
Atezolizumab 840 / Doxorubicin 60 / Cyclophosphamide 600, Breast Cancer, neoadjuvant, cycle 4-5. (PID2424)
Atezolizumab 840 / FLOT (Docetaxel 50 / Oxaliplatin 85 / Folinic Acid 200 / Fluorouracil 2600) - ATEZ1200, Adenocarcinoma Esophagogastric Junction and Stomach, perioperative, Cycle 9-17 (PID2564)
Atezolizumab 840 / FLOT (Docetaxel 50 / Oxaliplatin 85 / Folinic Acid 200 / Fluorouracil 2600), Adenocarcinoma Esophagogastric Junction and Stomach, perioperative, Cycle 1-4,5-8 (PID2563)
Atezolizumab 840 / Nab-Paclitaxel 100, Breast Cancer (PID63)
Atezolizumab 840 / Nab-Paclitaxel 125, Breast Cancer, neoadjuvant, cycle 1-3. (PID2423)
Atezolizumab 840 / Vemurafenib 720 / Cobimetinib 60, Malignant Melanoma, Cycle 2+ (PID2202)
Atezolizumab 840, Bladder Cancer, First Line (PID1658)
Atezolizumab 840, Bladder Cancer, Second Line (PID1660)
Atezolizumab 840, Non-Small Cell Lung Cancer, Second Line (PID1662)
Avapritinib 200, Systemic Mastocytosis (PID2071)
Avapritinib 300, Gastrointestinal Stroma Tumor (PID1689)
Avatrombopag 20, Immune Thrombocytopenia (PID1800)
Avelumab 800 / Axitinib 5, Renal Cell Carcinoma (PID1353)
Avelumab 800 / Ramucirumab 8 / Paclitaxel 80, Adenocarcinoma Esophagogastric Junction and Stomach (PID2565)
Avelumab 800 / Talazoparib 1, Endometrial Cancer (PID2173)
Avelumab 800, Gestational Trophoblastic Neoplasia (PID1612)
Avelumab 800, Bladder Cancer (PID2179)
Avelumab 800, Bladder Cancer, Maintenance (PID679)
Avelumab 800, Colorectal Carcinoma (PID2412)
Avelumab 800, Breast Cancer (PID66)
Avelumab 800, Merkel Cell Carcinoma (PID1076)
(PID2355)
Axitinib 5, Renal Cell Carcinoma (PID737)
Azacitidine 100, Acute Myeloid Leukemia and Myelodysplastic Syndrome after Allogeneic Stem Cell Transplantation (PID2302)
Azacitidine 100, Acute Myeloid Leukemia and Myelodysplastic Syndrome after Allogeneic Stem Cell Transplantation, Variant 1. (PID2320)
Azacitidine 300, Acute Myeloid Leukemia (PID1807)
Azacitidine 300, T-cell Lymphoma (PID2688)
Azacitidine 75 / Gilteritinib 120, Acute Myeloid Leukemia (PID2430)
Azacitidine 75 / Ivosidenib 500, Acute Myeloid Leukemia (PID2368)
Azacitidine 75 / Lenalidomide 25, Acute Myeloid Leukemia and Myelodysplastic Syndrome after Allogeneic Stem Cell Transplantation (PID827)
Azacitidine 75, Acute Myeloid Leukemia and Myelodysplastic Syndrome after Allogeneic Stem Cell Transplantation. (PID2327)
Azacitidine 75, Acute Myeloid Leukemia, over 65 years of age (PID700)
Azacitidine 75, Myelodysplastic Syndrome, High-Risk (PID616)
Azacitidine 75, Myelodysplastic Syndrome, Low risk (PID2317)
Azathioprine 2, Autoimmune Hemolytic Anemia, warm type (PID2008)
BEACOPP Basis, Hodgkin Lymphoma (PID474)
BEACOPP dosisescalated, Hodgkin Lymphoma (PID473)
BEAM - Carmustine 300 / Etoposide 200 / Cytarabine 200 / Melphalan 140, prior to autologous Stem Cell Transplantation, Autologous (PID280)
BeEAM - Bendamustine 100 / Etoposide 200 / Cytarabine 200 / Melphalan 140, prior to autologous Stem Cell Transplantation (PID879)
Belzutifan 120, von Hippel-Lindau disease (PID1947)
Bendamustine 100, Chronic Lymphocytic Leukemia (PID319)
Bendamustine 120, Hodgkin Lymphoma (PID2395)
Bendamustine 120, T-cell Lymphoma (PID1923)
Bendamustine 120, T-Cell Prolymphocyte Leukemia (PID1561)
Bendamustine 60 / Bortezomib 1.3 / Prednisolone 100, Multiple Myeloma (PID615)
Bendamustine 70 / Bortezomib 1.3 / Dexamethasone 20, Multiple Myeloma (PID740)
Bendamustine 75 / Lenalidomide 10 / Dexamethasone 40, Multiple Myeloma (PID2397)
Bendamustine 90 / Bortezomib 1.3 / Prednisolone 60, Multiple Myeloma, Cycle 1 (PID1550)
Bendamustine 90 / Bortezomib 1.3 / Prednisolone 60, Multiple Myeloma, Cycle 2-9 (PID1551)
Bendamustine 90, diffuse large B-non-Hodgkin Lymphoma, Lymphodepletion (PID1830)
BEP - Cisplatin 20 / Etoposide 100 / Bleomycin 30, Testicular Carcinoma, Good Prognosis. (PID771)
BEP - Cisplatin 20 / Etoposide 100 / Bleomycin 30, Testicular Carcinoma, Intermediate-High Risk (PID777)
BEP - Cisplatin 20 / Etoposide 100 / Bleomycin 30, Testicular Carcinoma, non-Seminoma, adjuvant (PID776)
Bevacizumab 10 / Carboplatin 5 / Doxorubicin Pegylated Liposomal 30, Ovarian Ca. (PID2187)
Bevacizumab 10 / Interferon Alpha-2a 9 M, Renal Cell Carcinoma (PID788)
Bevacizumab 10 / Lomustine 90, Glioblastoma (PID2019)
Bevacizumab 10, Glioblastoma (PID549)
Bevacizumab 15 / Gemcitabine 1000 / Carboplatin 4, Ovarian ca (PID126)
Bevacizumab 15 / Paclitaxel 175 / Carboplatin 5, Ovarian ca (PID1429)
Bevacizumab 15 / Paclitaxel 175 / Carboplatin 5, Cervical Cancer (PID2605)
Bevacizumab 15 / Paclitaxel 80 / liposomal Doxorubicin 20 / Carboplatin 1.5, Breast Cancer (PID754)
Bevacizumab 15, Endometrial Cancer (PID896)
Bevacizumab 15, Ovarian Carcinoma (PID495)
Bevacizumab 15, Ovarian Carcinoma, maintenance. (PID1430)
Bevacizumab 15, Soft Tissue Sarcoma (PID1826)
Bevacizumab 15, Cervical Cancer, maintenance (PID2611)
Bevacizumab 7.5 / Irinotecan 150 / Tegafur 40, Colorectal Carcinoma (PID1404)
Bevacizumab 7.5 / Oxaliplatin 130 / Tegafur 40, Colorectal Carcinoma (PID2177)
Bevacizumab 7.5, Ovarian Carcinoma (PID501)
Bevacizumab 7.5, Radionecrosis (PID2138)
Binimetinib 45, Ovarian Ca (PID2671)
Bleomycin 15, Non-Small Cell Lung Cancer (PID2375)
Blinatumomab (9/28), Acute Lymphoblastic Leukaemia, Cycle 1 (PID107)
Blinatumomab (9/28), ALL/NHL, cycle 1 (PID2117)
Blinatumomab 15, Acute Lymphoblastic Leukaemia, MRD positive (PID1140)
Blinatumomab 28, Acute Lymphoblastic Leukaemia, maintenance (PID313)
Blinatumomab 28, Acute Lymphoblastic Leukaemia, Cycle 2-5 (PID68)
Blinatumomab 28, ALL/NHL, cycle 2-4 (PID2118)
Bortezomib 1.0 / Doxorubicin 9 / Dexamethasone 40, Multiple Myeloma (PID2428)
Bortezomib 1.3 / Cyclophosphamide 300 / Dexamethasone 40, Multiple Myeloma, Cycle 2.4 (PID1964)
Bortezomib 1.3 / Daratumumab (8/8/16) / Dexamethasone (20/20), Multiple Myeloma, Cycle 1 (PID1432)
Bortezomib 1.3 / Daratumumab (8/8/16) / Lenalidomide 25 / Dexamethasone 20, Induction, Multiple Myeloma, Cycle 1 (PID1718)
Bortezomib 1.3 / Daratumumab (8/8/16) / Melphalan 9 / Prednisolone 60, Multiple Myeloma, Cycle 1 (PID1433)
Bortezomib 1.3 / Daratumumab (8/8/16) / Thalidomide 100 / Dexamethasone 40, Multiple Myeloma, Cycle 1 (PID1482)
Bortezomib 1.3 / Daratumumab 16 / Dexamethasone (20/20) - Daratumumab 16 maintenance, Multiple Myeloma, Cycle 9+ (PID820)
Bortezomib 1.3 / Daratumumab 16 / Dexamethasone (20/20), Multiple Myeloma, Cycle 1 (PID817)
Bortezomib 1.3 / Daratumumab 16 / Dexamethasone (20/20), Multiple Myeloma, Cycle 2-3 (PID818)
Bortezomib 1.3 / Daratumumab 16 / Dexamethasone (20/20), Multiple Myeloma, Cycle 4-8 (PID819)
Bortezomib 1.3 / Daratumumab 16 / Lenalidomide 25 / Dexamethasone 20 - Daratumumab 16 / Lenalidomide 10, maintenance, Multiple Myeloma (PID1721)
Bortezomib 1.3 / Daratumumab 16 / Lenalidomide 25 / Dexamethasone 20, Induction, Multiple Myeloma, Cycle 2-4 (PID1719)
Bortezomib 1.3 / Daratumumab 16 / Lenalidomide 25 / Dexamethasone 20, consolidation, Multiple Myeloma, cycle 5-6 (PID1720)
Bortezomib 1.3 / Daratumumab 16 / Melphalan 9 / Prednisolone 60 - Daratumumab 16 maintenance, Multiple Myeloma, Cycle 10+ (PID461)
Bortezomib 1.3 / Daratumumab 16 / Melphalan 9 / Prednisolone 60, Multiple Myeloma, cycle 1 (PID588)
Bortezomib 1.3 / Daratumumab 16 / Melphalan 9 / Prednisolone 60, Multiple Myeloma, Cycle 2-9 (PID651)
Bortezomib 1.3 / Daratumumab 16 / Thalidomide 100 / Dexamethasone (40/20), Multiple Myeloma, Cycle 3-4 (PID1484)
Bortezomib 1.3 / Daratumumab 16 / Thalidomide 100 / Dexamethasone 20, Multiple Myeloma, consolidation (PID1485)
Bortezomib 1.3 / Daratumumab 16 / Thalidomide 100 / Dexamethasone 40, Multiple Myeloma, Cycle 2 (PID1483)
Bortezomib 1.3 / Daratumumab 1800 / Lenalidomide 25 / Dexamethasone 20 - Daratumumab 1800 / Lenalidomide 10, maintenance, Multiple Myeloma (PID1725)
Bortezomib 1.3 / Daratumumab 1800 / Dexamethasone (20/20) - Daratumumab 1800 Maintenance, Multiple Myeloma (PID1615)
Bortezomib 1.3 / Daratumumab 1800 / Dexamethasone (20/20), Multiple Myeloma, Cycle 1-3 (PID1613)
Bortezomib 1.3 / Daratumumab 1800 / Dexamethasone (20/20), Multiple Myeloma, Cycle 4-8 (PID1614)
Bortezomib 1.3 / Daratumumab 1800 / Dexamethasone 20 / Thalidomide 100 - Daratumumab 1800 Maintenance, Multiple Myeloma (PID1635)
Bortezomib 1.3 / Daratumumab 1800 / Lenalidomide 25 / Dexamethasone 20, consolidation, Multiple Myeloma, cycle 5-6 (PID1724)
Bortezomib 1.3 / Daratumumab 1800 / Lenalidomide 25/ Dexamethasone 20, induction, Multiple Myeloma, cycle 1-4 (PID1723)
Bortezomib 1.3 / Daratumumab 1800 / Melphalan 9 / Prednisolone 60 - Daratumumab 1800 Maintenance, Multiple Myeloma (PID1619)
Bortezomib 1.3 / Daratumumab 1800 / Melphalan 9 / Prednisolone 60, Multiple Myeloma, Cycle 1 (PID1617)
Bortezomib 1.3 / Daratumumab 1800 / Melphalan 9 / Prednisolone 60, Multiple Myeloma, Cycle 2-9 (PID1618)
Bortezomib 1.3 / Daratumumab 1800 / Thalidomide 100 / Dexamethasone (40/20), Multiple Myeloma, Cycle 3-4 (PID1629)
Bortezomib 1.3 / Daratumumab 1800 / Thalidomide 100 / Dexamethasone 20, Multiple Myeloma, consolidation (PID1630)
Bortezomib 1.3 / Daratumumab 1800 / Thalidomide 100 / Dexamethasone 40, Multiple Myeloma, Cycle 1-2 (PID1628)
Bortezomib 1.3 / Dexamethasone 40, Induction, Multiple Myeloma (PID1164)
Bortezomib 1.3 / Isatuximab 10 / Lenalidomide 25 / Dexamethasone 20, multiple myeloma, induction, cycle 1 (PID2660)
Bortezomib 1.3 / Isatuximab 10 / Lenalidomide 25 / Dexamethasone 20, multiple myeloma, induction, cycle 2-4 (PID2661)
Bortezomib 1.3 / Lenalidomide 15 / Dexamethasone 40, Multiple Myeloma, consolidation (PID1965)
Bortezomib 1.3 / Lenalidomide 25 / Dexamethasone 10, Consolidation without transplantation, Multiple Myeloma (PID1037)
Bortezomib 1.3 / Lenalidomide 25 / Dexamethasone 10, Multiple Myeloma, Consolidation after Autologous Stem Cell Transplantation. (PID1040)
Bortezomib 1.3 / Lenalidomide 25 / Dexamethasone 20, Induction, Multiple Myeloma (PID1036)
Bortezomib 1.3 / Melphalan 9 / Prednisolone 60, Multiple Myeloma, Cycle 1 (PID1003)
Bortezomib 1.3 / Melphalan 9 / Prednisolone 60, Multiple Myeloma, Cycle 1-4 (PID533)
Bortezomib 1.3 / Melphalan 9 / Prednisolone 60, Multiple Myeloma, Cycle 2-5 (PID1004)
Bortezomib 1.3 / Melphalan 9 / Prednisolone 60, Multiple Myeloma, Cycle 5-9 (PID534)
Bortezomib 1.3 / Panobinostat 20 / Dexamethasone 20, Multiple Myeloma, Cycle 1-8 (PID611)
Bortezomib 1.3 / Panobinostat 20 / Dexamethasone 20, Multiple Myeloma, Cycle 9-16 (PID612)
Bortezomib 1.3 / Doxorubicin Pegylated Liposomal 30 / Dexamethasone 40, Multiple Myeloma, Cycle 1.3 (PID1963)
Bortezomib 1,3 / pegylated liposomal Doxorubicin 30, Multiple Myeloma (PID1589)
Bortezomib 1.3 / Pomalidomide 4 / Dexamethasone 20 , Multiple Myeloma, Cycle 9+ (PID1592)
Bortezomib 1.3 / Pomalidomide 4 / Dexamethasone 20, Multiple Myeloma, Cycle 1-8 (PID1591)
Bortezomib 1.3 / Prednisolone 60, maintenance, Multiple Myeloma (PID1005)
Bortezomib 1.3 / Rituximab 375 / Bendamustine 90, indolent B-Non-Hodgkin Lymphoma and Mantle Cell Lymphoma (PID2678)
Bortezomib 1.3 / Rituximab 375 / Cyclophosphamide 750 / Doxorubicin 50 / Prednisolone 100, Mantle Cell Lymphoma (PID527)
Bortezomib 1.3 / Thalidomide 100 / Dexamethasone 40, Multiple Myeloma (PID2427)
Bortezomib 1,3 s.c., Mantle Cell Lymphoma (PID277)
Bortezomib 1,3, AL Amyloidosis (PID1510)
Bortezomib 1,3, Autoimmune Hemolytic Anemia, Cold Agglutinin Disease (PID2023)
Bortezomib 1.3, Cutaneous T-cell Lymphoma (PID2459)
Bortezomib 1,3, Waldenström's disease, cycle 1 (PID2343)
Bortezomib 1,3, TEMPI syndrome (PID2182)
Bortezomib 1.5 / Cyclophosphamide 300 / Dexamethasone 40, Multiple Myeloma, cycle 3-4 (PID1853)
Bortezomib 1.6 / Rituximab 375 - Bortezomib 1.6 Waldenström's disease, cycle 2+3+5+6 (PID1266)
Bortezomib 1.6 / Rituximab 375 / Dexamethasone 40, Waldenström's disease, cycle 2,5 (PID2342)
Bortezomib 1.6 / Rituximab 375, Waldenström's disease, cycle 1+4 (PID1235)
Bortezomib 1.6, AL Amyloidosis (PID1509)
Bortezomib 1.6, Kaposi's Sarcoma (PID2028)
Bortezomib 1.6, Waldenström's disease, cycle 3-4 (PID2344)
Bosutinib 500, Chronic Myeloid Leukemia (PID946)
Brentuximab Vedotin 1.8 / Bendamustine 90, Hodgkin Lymphoma (PID2363)
Brentuximab Vedotin 1.8 / Cyclophosphamide 1250 / Doxorubicin 40 / Etoposide 150 / Dacarbazine 250 / Dexamethasone 40, Hodgkin Lymphoma (PID962)
Brentuximab Vedotin 1.8 / Dacarbazine 375 - Brentuximab Vedotin 1.8, Hodgkin Lymphoma, Cycle 13-16 (PID2365)
Brentuximab Vedotin 1.8 / Dacarbazine 375, Hodgkin Lymphoma, Cycle 1-12 (PID2364)
Brentuximab Vedotin 1.8 / Nivolumab 240, Non-Hodgkin Lymphoma, Cycle 1 (PID1516)
Brentuximab Vedotin 1.8 / Nivolumab 240, Non-Hodgkin Lymphoma, Cycle 2+ (PID1515)
Brentuximab Vedotin 1.8 / Nivolumab 3, Hodgkin Lymphoma (PID90)
Brentuximab Vedotin 1.8 / Nivolumab 3, Hodgkin Lymphoma, cycle 1 (PID1903)
Brentuximab Vedotin 1.8 / Nivolumab 3, Hodgkin Lymphoma, cycle 2-4 (PID1904)
Brentuximab Vedotin 1.8, maintenance, Hodgkin Lymphoma (PID849)
Brentuximab Vedotin 1.8, Hodgkin Lymphoma (PID475)
Brentuximab Vedotin 1.8, cutaneous T-cell lymphoma (PID1389)
Brentuximab Vedotin 1.8, T-cell Lymphoma (PID1925)
Brigatinib 180, Non-Small Cell Lung Cancer, First-Line, Cycle 2+ (PID49)
Brigatinib 180, Non-Small Cell Lung Cancer, Second Line, Cycle 2+ (PID55)
Brigatinib 90/180, Non-Small Cell Lung Cancer, First-Line, Cycle 1 (PID48)
Brigatinib 90/180, Non-Small Cell Lung Cancer, Second Line, Cycle 1 (PID54)
Burosumab 0.3, Osteomalacia, tumor-induced (PID2057)
Buserelin 9.45, Prostate Cancer (PID1523)
Busulfan 0.8 / Melphalan 140, Ewing Sarcoma, Autologous Stem Cell Transplantation (PID571)
Busulfan 1 / Melphalan 140, Ewing Sarcoma, Autologous Stem Cell Transplantation (PID76)
Busulfan 2, Polycythaemia Vera (PID2299)
BV-ICE - Brentuximab Vedotin 1.5 / Etoposide 100 / Carboplatin 5 / Ifosfamide 5, Hodgkin Lymphoma (PID1902)
BV-ICE - Brentuximab Vedotin 1.8 / Etoposide 100 / Carboplatin 5 / Ifosfamide 5, T-cell Lymphoma (PID2420)
Cabazitaxel 20 / Prednisolone 10, Prostate Cancer, First Line (PID1129)
Cabazitaxel 20 / Prednisolone 10, Prostate Cancer, Second Line (PID1134)
Cabazitaxel 25 / Carboplatin 4 / Prednisolone 5 Prostate Cancer (PID2310)
Cabazitaxel 25 / Prednisolone 10, Prostate Cancer, First Line (PID1104)
Cabazitaxel 25 / Prednisolone 10, Prostate Cancer, Second Line (PID645)
Cabazitaxel 25, Soft Tissue Sarcoma (PID2172)
Cabozantinib 140, Thyroid Cancer (PID825)
Cabozantinib 60, Hepatocellular Carcinoma (PID1558)
Cabozantinib 60, Adrenocortical Carcinoma (PID2625)
Cabozantinib 60, Renal Cell Carcinoma, second-line (PID736)
Cabozantinib 60, Osteosarcoma / Ewing Sarcoma (PID1869)
Cabozantinib 60, Pheochromocytoma / Paraganglioma (PID2624)
CAD - Cyclophosphamide 1000 / Doxorubicin 15 / Dexamethasone 40, stem cell mobilization, Multiple Myeloma (PID530)
CAMP - Methylprednisolone (750/375) / Doxorubicin 40 / Cisplatin 20, Thymoma (PID1842)
CAP - Cisplatin 50 / Doxorubicin 50 / Cyclophosphamide 500, Thymoma (PID362)
CAP - Cisplatin 50 / Doxorubicin 50 / Cyclophosphamide 600, Salivary Gland Tumor (PID1696)
Capecitabine 1000 / Bevacizumab 15, Breast Cancer (PID370)
Capecitabine 1000 / Bevacizumab 7.5, Colorectal Carcinoma (PID438)
Capecitabine 1000 / Cisplatin 60, Gastric Cancer, adjuvant (PID695)
Capecitabine 1000 / Cisplatin 80, adenocarcinoma esophagogastric junction and stomach (PID1417)
Capecitabine 1000 / Docetaxel 75, Breast Cancer, adjuvant (PID1643)
Capecitabine 1000 / Epirubicin 75 / Cyclophosphamide 500, Breast Cancer, adjuvant (PID1644)
Capecitabine 1000 / Irinotecan 180, Bile Duct Carcinoma (PID1949)
Capecitabine 1000 / Irinotecan 250, adenocarcinoma esophagogastric junction and stomach (PID1418)
Capecitabine 1000 / Irinotecan 250, Colorectal Carcinoma (PID1743)
Capecitabine 1000 / Margetuximab 15, Breast Cancer (PID1871)
Capecitabine 1000 / Oxaliplatin 130, Bile Duct Carcinoma (PID1358)
Capecitabine 1000 / Oxaliplatin 130, Carcinoma in an Occult Primary (PID1190)
Capecitabine 1000 / Oxaliplatin 130, Colorectal Carcinoma (PID443)
Capecitabine 1000 / Oxaliplatin 130, Rectal Cancer, neoadjuvant (PID2054)
Capecitabine 1000 / Oxaliplatin 70, colorect. Carcinoma (PID457)
Capecitabine 1000 / Paclitaxel 175, Breast Cancer (PID380)
Capecitabine 1000, Breast Carcinoma (PID2128)
Capecitabine 1250 / Docetaxel 75, Breast Cancer (PID1685)
Capecitabine 1250, Bile Duct Carcinoma, adjuvant (PID1183)
Capecitabine 1250, Colon Cancer adjuvant (PID463)
Capecitabine 1250, Colorectal Carcinoma (PID434)
Capecitabine 1250, Breast Cancer, adjuvant (PID1370)
Capecitabine 1250, Ovarian Carcinoma (PID2191)
Capecitabine 1250, Rectal Cancer, adjuvant, part C (PID2052)
Capecitabine 1250, Rectal Cancer, neo-/adjuvant, Part B (PID422)
Capecitabine 625, Breast Cancer, adjuvant (PID2703)
Capecitabine 750 / Temozolomide 200, pancreatic neuroendocrine carcinoma (PID1313)
Capecitabine 800 / Radiation, Rectal Cancer, neoadjuvant, part B (PID2050)
Capecitabine 825 / Mitomycin 12 / Radiation, Anal Carcinoma (PID481)
Capecitabine 825 / Mitomycin 12 / Radiation, Bladder Cancer (PID2505)
Capecitabine 825 / Radiation, Gastric Cancer, adjuvant (PID2243)
Capecitabine 825 / Radiation, Rectal Cancer, Neo/Adjuvant, Part A (PID421)
Capecitabine 825 / Radiation, Rectal Cancer, neoadjuvant (PID2265)
Capecitabine 830 / Radiation, Pancreatic Cancer (PID1968)
CapIri (Capecitabine 1000 / Irinotecan 200) / Bevacizumab 7.5, Colorectal Carcinoma (PID447)
Capivasertib 400 / Fulvestrant 500 / Goserelin 3.6, Breast Cancer, Cycle 1 (PID2609)
Capivasertib 400 / Fulvestrant 500 / Goserelin 3.6, Breast Cancer, Cycle 2+ (PID2610)
Caplacizumab 10, Thrombotic Thrombocytopenic Purpura, cycle 1 (PID2111)
Caplacizumab 10, Thrombotic Thrombocytopenic Purpura, cycle 2+ (PID2112)
Capmatinib 400, Non-Small Cell Lung Cancer (PID1793)
CAPOX (Capecitabine 1000 / Oxaliplatin 130) / Cetuximab (400/250), Colorectal Carcinoma, Cycle 1 (PID1820)
CAPOX (Capecitabine 1000 / Oxaliplatin 130) / Cetuximab 250, Colorectal Carcinoma, Cycle 2+ (PID1821)
CAPOX (Capecitabine 1000 / Oxaliplatin 130) / Nivolumab 360, Esophagogastric Carcinoma, Esophagogastric junction and Stomach (PID1906)
CAPOX (Capecitabine 1000 / Oxaliplatin 130) / Panitumumab 9, Colorectal Carcinoma (PID692)
CAPOX (Capecitabine 1000 / Oxaliplatin 130), Colon Cancer, adjuvant (PID460)
CAPOX (Capecitabine 375 / Oxaliplatin 78), Esophagogastric Carcinoma, Esophagus, Esophagogastric junction and Stomach (PID1794)
CAPOX (Capecitabine 750 / Oxaliplatin130) / Bevacizumab 7.5, Small bowel Cancer or Ampullary Cancer (PID490)
CAPOX (Oxaliplatin 130 / Capecitabine 1000) / Bevacizumab 7.5, Colorectal Carcinoma (PID444)
CAPOX (Oxaliplatin 130 / Capecitabine 1000) / TRAS 6, Adenocarcinoma Esophagogastric Junction and Stomach, Cycle 2-6 (PID1301)
CAPOX (Oxaliplatin 130 / Capecitabine 1000) / Trastuzumab 8, Adenocarcinoma Esophagogastric Junction and Stomach, C1 (PID1258)
CAPOX - Capecitabine 1000 / Oxaliplatin 130, Adenocarcinoma Esophagogastric Junction and Stomach, adjuvant, part A+C (PID689)
CAPOX - Capecitabine 1000 / Oxaliplatin 130, Gastric Cancer, adjuvant (PID696)
CAPOX / Radiation - Capecitabine 825 / Oxaliplatin 40 / Radiation, adenocarcinoma esophagogastric junction and stomach, adjuvant, Part B (PID684)
Carboplatin 1.5 / Radiation, Head and Neck Tumors (PID1282)
Carboplatin 100 / Radiation, Nasopharyngeal Carcinoma, Part A (PID1781)
Carboplatin 150, Breast Cancer (PID2374)
Carboplatin 2 / Radiation followed by Carboplatin 4.5 / Etoposide 80, Merkel Cell Carcinoma Part B (PID1111)
Carboplatin 2 / Radiation followed by Carboplatin 4.5, Etoposide 80, Merkel Cell Carcinoma Part A (PID109)
Carboplatin 2 / Radiation, Squamous Cell Carcinoma of the Skin (PID2178)
Carboplatin 2 / Radiation, Cervical Cancer (PID1939)
Carboplatin 300 / Etoposide 100, Lung Carcinoma, Small Cell (PID210)
Carboplatin 300 / Etoposide 140 / Vincristine 2, Small Cell Lung Carcinoma, Small Cell (PID207)
Carboplatin 5 / Cyclophosphamide 600, Breast Cancer (PID101)
Carboplatin 5 / Etoposide 100, Small Cell Lung Carcinoma, Small Cell (PID209)
Carboplatin 5 / Etoposide 100, Merkel Cell Carcinoma (PID1107)
Carboplatin 5 / Etoposide 110 / Vincristine 2, Lung Carcinoma, Small Cell (limited disease) (PID1477)
Carboplatin 5 / Etoposide 140, Lung Carcinoma, Small Cell (PID204)
Carboplatin 5 / Etoposide 80, Lung Carcinoma, Small Cell (PID208)
Carboplatin 5 / Etoposide 90 / Vincristine 2, Lung Carcinoma, Small Cell (extensive disease) (PID1476)
Carboplatin 5 / Fluorouracil 1000, Nasopharyngeal Carcinoma, Part B (PID1782)
Carboplatin 5 / Vinorelbine 25, Non-Small Cell Lung Carcinoma (PID284)
Carboplatin 5, Ovarian ca (PID1332)
Carboplatin 6 / Etoposide 100 / Radiation, Small Cell Lung Cancer (PID2267)
Carboplatin 6 / Etoposide 120, Ovarian Tumor (PID2188)
Carboplatin 6, Breast Cancer (PID1940)
Carboplatin 7, Testicular Carcinoma, Seminoma, adjuvant (PID775)
Carboplatin 7, Ovarian ca (PID1428)
Carboplatin 70 / Fluorouracil 600 / Radiation, Oropharyngeal Carcinoma (PID1708)
Carfilzomib (20/27) / Bendamustine 70 / Dexamethasone 20, Multiple Myeloma, Cycle 1 (PID2406)
Carfilzomib (20/27) / Lenalidomide 25 / Dexamethasone 40, Multiple Myeloma Cycle 1 (PID522)
Carfilzomib (20/27) / Pomalidomide 4 / Dexamethasone 40, Multiple Myeloma Cycle 1 (PID1586)
Carfilzomib (20/36) / Cyclophosphamide 300 / Dexamethasone 40 , Multiple Myeloma, Cycle 1, Variant 1 (PID1458)
Carfilzomib (20/36) / Cyclophosphamide 300 / Dexamethasone 40, Multiple Myeloma, Cycle 1 (PID1455)
Carfilzomib (20/36) / Cyclophosphamide 500 / Dexamethasone 40, Multiple Myeloma, second line, cycle 1 (PID1460)
Carfilzomib (20/56) / Dexamethasone 20, Multiple Myeloma, Cycle 1 (PID733)
Carfilzomib (20/70) / Daratumumab (8/8/16) / Dexamethasone (20/20), Multiple Myeloma, Cycle 1 (PID1438)
Carfilzomib 20 / Rituximab 375 / Dexamethasone 20, Waldenström, cycle 1 (PID2586)
Carfilzomib 27 / Bendamustine 70 / Dexamethasone 20 - Carfilzomib 27 / Dexamethasone 20, Multiple Myeloma, Maintenance, Cycle 9+ (PID2408)
Carfilzomib 27 / Bendamustine 70 / Dexamethasone 20, Multiple Myeloma, Cycle 2-8 (PID2407)
Carfilzomib 27 / Lenalidomide 25 / Dexamethasone 40 - Lenalidomide 25 / Dexamethasone 40, maintenance, Multiple Myeloma (PID525)
Carfilzomib 27 / Lenalidomide 25 / Dexamethasone 40, Multiple Myeloma Cycle 13-18 (PID524)
Carfilzomib 27 / Lenalidomide 25 / Dexamethasone 40, Multiple Myeloma Cycle 2-12 (PID523)
Carfilzomib 27 / Pomalidomide 4 / Dexamethasone 20, Multiple Myeloma, Cycle 7+ (PID1588)
Carfilzomib 27 / Pomalidomide 4 / Dexamethasone 40, Multiple Myeloma Cycle 2-6 (PID1587)
Carfilzomib 36 / Cyclophosphamide 300 / Dexamethasone 40 - Carfilzomib 36 maintenance, Multiple Myeloma (PID1457)
Carfilzomib 36 / Cyclophosphamide 300 / Dexamethasone 40, Multiple Myeloma, Cycle 2-9 (PID1456)
Carfilzomib 36 / Cyclophosphamide 300 / Dexamethasone 40, Multiple Myeloma, Cycle 2-9, Variant 1 (PID1459)
Carfilzomib 36 / Cyclophosphamide 500 / Dexamethasone 40 - Carfilzomib 36 maintenance, Multiple Myeloma, second line, C13-24 (PID1463)
Carfilzomib 36 / Cyclophosphamide 500 / Dexamethasone 40 - Carfilzomib 36 maintenance, Multiple Myeloma, second line, cycle 7-12 (PID1462)
Carfilzomib 36 / Cyclophosphamide 500 / Dexamethasone 40, Multiple Myeloma, second line, cycle 2-6 (PID1461)
Carfilzomib 36 / Rituximab 375 / Dexamethasone 20, Waldenström, cycle 2-6 (PID2587)
Carfilzomib 36 / Rituximab 375 / Dexamethasone 20, Waldenström, cycle 7-14 (PID2588)
Carfilzomib 56 / Dexamethasone 20, Multiple Myeloma, Cycle 2+ (PID734)
Carfilzomib 70 / Cyclophosphamide 300 / Dexamethasone 40 - Carfilzomib 70 Maintenance, Multiple Myeloma (PID1742)
Carfilzomib 70 / Cyclophosphamide 300 / Dexamethasone 40, Multiple Myeloma (PID1741)
Carfilzomib 70 / Daratumumab 16 / Dexamethasone (20/20), Multiple Myeloma, Cycle 2 (PID1439)
Carfilzomib 70 / Daratumumab 16 / Dexamethasone (20/20/40), Multiple Myeloma, Cycle 3-6 (PID1440)
Carfilzomib 70 / Daratumumab 16 / Dexamethasone (20/20/40), Multiple Myeloma, Cycle 7+ (PID1441)
Carmustine 400 / Thiotepa 5, consolidation before autologous Stem Cell Transplantation, CNS- Non-Hodgkin Lymphoma (PID890)
CE (Carboplatin 500 / Etoposide 500), Testicular Carcinoma (PID1574)
Cemiplimab 350 / Paclitaxel 200 / Carboplatin 6, Non-Small Cell Lung Cancer, Cycle 1-4 (PID2275)
Cemiplimab 350 / Paclitaxel 200 / Cisplatin 75, Non-Small Cell Lung Cancer, Cycle 1-4 (PID2274)
Cemiplimab 350 / Pemetrexed 500 / Carboplatin 6, Non-Small Cell Lung Cancer, Cycle 1-4 (PID2271)
Cemiplimab 350 / Pemetrexed 500 / Cisplatin 75, Non-Small Cell Lung Cancer, Cycle 1-4 (PID2273)
Cemiplimab 350 / Pemetrexed 500, Non-Small Cell Lung Cancer, Cycle 5+ (PID2272)
Cemiplimab 350, Basal Cell Carcinoma (PID1867)
Cemiplimab 350, Non-Small Cell Lung Carcinoma (PID1744)
Cemiplimab 350, Non-Small Cell Lung Cancer, Cycle 5+ (PID2276)
Cemiplimab 350, Squamous Cell Carcinoma of the Skin (PID1379)
Cemiplimab 350, Squamous Cell Carcinoma of the Skin, after organ transplantation (PID2570)
Cemiplimab 350, Squamous Cell Carcinoma of the Skin, neoadjuvant (PID2147)
Cemiplimab 350, Cervical Cancer (PID1981)
Ceritinib 450, Non-Small Cell Lung Cancer, First Line (PID1152)
Ceritinib 450, Non-Small Cell Lung Cancer, Second Line (PID811)
Cetuximab (400/250) / Capecitabine 800 / Irinotecan 200, Colorectal Carcinoma, Cycle 1 (PID1818)
Cetuximab (400/250) / Cisplatin 100, Head and Neck Tumors, Cycle 1 (PID1246)
Cetuximab (400/250) / Cisplatin 80 / Vinorelbine 25, Non-Small Cell Lung Cancer, Cycle 1 (PID190)
Cetuximab (400/250) / Docetaxel 75 / Cisplatin 100 / Fluorouracil 700, Head and Neck Tumors, Cycle 1 (PID1348)
Cetuximab (400/250) / Docetaxel 75 / Cisplatin 75, Head and Neck Tumors, Cycle 1 (PID1275)
Cetuximab (400/250) / Irinotecan 350, Colorectal Carcinoma, Cycle 1 (PID425)
Cetuximab (400/250) / Paclitaxel 175 / Cisplatin 75, Head and Neck Tumors, Cycle 1 (PID1273)
Cetuximab 250 / Capecitabine 800 / Irinotecan 200, Colorectal Carcinoma, Cycle 2+ (PID1819)
Cetuximab 250 / Carboplatin 5 / Fluorouracil 1000, Head and Neck Tumors, C2+ (PID337)
Cetuximab 250 / Cisplatin 100, Head and Neck Tumors, Cycle 2+ (PID1271)
Cetuximab 250 / Cisplatin 80 / Vinorelbine 25 - Cetuximab 250 Maintenance, Non-Small Cell Lung Cancer (PID192)
Cetuximab 250 / Cisplatin 80 / Vinorelbine 25, Non-Small Cell Lung Cancer, Cycle 2-6 (PID191)
Cetuximab 250 / Docetaxel 75 / Cisplatin 75, Head and Neck Tumors, Cycle 2+ (PID1276)
Cetuximab 250 / Irinotecan 350, Colorectal Carcinoma, Cycle 2+ (PID426)
Cetuximab 250 / Paclitaxel 175 / Cisplatin 75, Head and Neck Tumors, Cycle 2+ (PID1274)
Cetuximab 250 / Paclitaxel 30 / Carboplatin 1 / Radiation, Head and Neck Tumors, Cycle 7-11 (PID1244)
Cetuximab 250 / Paclitaxel 40 / Carboplatin 2 / Radiation, Head and Neck Tumors, Cycle 2+ (PID621)
Cetuximab 250 / Paclitaxel 80, Head and Neck Tumors, Cycle 2+ (PID708)
Cetuximab 250 / Paclitaxel 90 / Carboplatin 2, Head and Neck Tumors, Cycle 2-6 (PID1243)
Cetuximab 250 / Radiation, Head and Neck Tumors, Cycle 2+ (PID1195)
Cetuximab 250 / Radiation, Squamous Cell Carcinoma of the Skin, Cycle 2+ (PID2164)
Cetuximab 250, Colorectal Carcinoma, Cycle 2+ (PID424)
Cetuximab 250, Head and Neck Tumors, Cycle 2+ (PID1221)
Cetuximab 250, Squamous Cell Carcinoma of the Skin, Cycle 2+ (PID2166)
Cetuximab 400 / Carboplatin 5 / Fluorouracil 1000, Head and Neck Tumors, C1 (PID623)
Cetuximab 400 / Paclitaxel 40 / Carboplatin 2 / Radiation, Head and Neck Tumors, Cycle 1 (PID622)
Cetuximab 400 / Paclitaxel 80, Head and Neck Tumors, Cycle 1 (PID707)
Cetuximab 400 / Paclitaxel 90 / Carboplatin 2, Head and Neck Tumors, Cycle 1 (PID1242)
Cetuximab 400 / Radiation, Head and Neck Tumors, Cycle 1 (PID1194)
Cetuximab 400 / Radiation, Squamous Cell Carcinoma of the Skin, Cycle 1 (PID2163)
Cetuximab 400, Colorectal Carcinoma, Cycle 1 (PID423)
Cetuximab 400, Head and Neck Tumors, Cycle 1 (PID1220)
Cetuximab 400, Squamous Cell Carcinoma of the Skin, Cycle 1 (PID2165)
Cetuximab 500 / Docetaxel 50, Head and Neck Tumors (PID1277)
Cetuximab 500 / Irinotecan 180 / Vemurafenib 960, Colorectal Carcinoma (PID1746)
Cetuximab 500, Head and Neck Tumors (PID1241)
Chlorambucil (0.4-0.7), Chronic Lymphocytic Leukemia, cycle 1-4 (PID320)
Chlorambucil 0.8, Chronic Lymphocytic Leukemia, cycle 5+ (PID868)
Chlorambucil 10, B-Non-Hodgkin Lymphoma (PID2334)
Chlorambucil 6, MALT lymphoma, cycle 1 (PID2568)
Chlorambucil 6, MALT lymphoma, cycle 2-5 (PID2569)
CHOEP 14 - Cyclophosphamide 750 / Doxorubicin 50 / Etoposide 100 / Vincristine 2 / Prednisolone 100, peripheral T-cell lymphoma (PID719)
CHOP 14 - Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 100, peripheral T-cell lymphoma (PID821)
CHOP 21 - Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 100, T-cell Lymphoma (PID1799)
CHOP 21 - Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 100, T-cell Lymphoma, Variant 1 (PID1773)
CHOP 21 - Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 40 followed by IVE/MTX - Ifosfamide 3 / Epirubicin 50 / Etoposide 200 / Methotrexate 1500 x 3, Enteropathy-associated T-cell lymphoma, Part A (PID1650)
Cisplatin (50/50) / Doxorubicin 60, Osteosarcoma (PID1362)
Cisplatin 100 / Bleomycin 25 / Ifosfamide 2, Testicular Carcinoma (PID2143)
Cisplatin 100 / Capecitabine 1000, Nasopharyngeal Carcinoma (PID1784)
Cisplatin 100 / Etoposide 100, Lung Carcinoma, Small Cell (PID201)
Cisplatin 100 / Etoposide 100, Non-Small Cell Lung Cancer, Adjuvant (PID243)
Cisplatin 100 / Fluorouracil 1000 / Radiation, carcinoma esophagus and gastroesophageal junction, neoadjuvant (PID1519)
Cisplatin 100 / Fluorouracil 1000 / Radiation, Nasopharyngeal Carcinoma (PID1737)
Cisplatin 100 / Fluorouracil 1000, Esophageal Cancer (PID135)
Cisplatin 100 / Fluorouracil 1000, Squamous Cell Carcinoma of the Skin (PID2385)
Cisplatin 100 / Fluorouracil 800, adenocarcinoma esophagus, esophagogastric junction and stomach (PID136)
Cisplatin 100 / Fluorouracil 960, Penile Carcinoma (PID1443)
Cisplatin 100 / Gemcitabine 1000, Pleural Mesothelioma (PID373)
Cisplatin 100 / Gemcitabine 1250, Carcinoma of Unknown Primary (PID618)
Cisplatin 100 / Radiation, Bladder Cancer (PID1668)
Cisplatin 100 / Radiation, Head and Neck Tumors (PID1334)
Cisplatin 100 / Radiation, Head and Neck Tumors (PID1640)
Cisplatin 100 / Radiation, Head and Neck Tumors, adjuvant (PID1291)
Cisplatin 100 / Radiation, Nasopharyngeal Carcinoma, Part A (PID1714)
Cisplatin 100 / Vinblastine 5 / Radiation, Non-Small Cell Lung Cancer (PID857)
Cisplatin 100, Head and Neck Tumors (PID1245)
Cisplatin 12 / Fluorouracil 600 / Radiation, Head and Neck Tumors, cycle 1-2 (PID2059)
Cisplatin 16 / fluorouracil 600, Head and Neck Tumors, cycle 3 (PID2060)
Cisplatin 20 / Etoposide 100, Gestational Trophoblastic Neoplasia, induction (PID1608)
Cisplatin 20 / Etoposide 75 / Ifosfamide 1,2, Small Cell Lung Carcinoma (PID233)
Cisplatin 20 / Fluorouracil 600, Head and Neck Tumors, cycle 4 (PID2062)
Cisplatin 20 / Fluorouracil 800 / Radiation, Head and Neck Tumors (PID2066)
Cisplatin 20 / Ifosfamide 1.2 / Vinblastine 0.11, Testicular Carcinoma (PID2039)
Cisplatin 20 / Vinorelbine 12.5 / Radiation, Non-Small Cell Lung Cancer (PID669)
Cisplatin 25 / Etoposide 100 / Radiation, Small Cell Lung Carcinoma, Small Cell (PID1256)
Cisplatin 25 / Etoposide 100, Merkel Cell Carcinoma (PID1108)
Cisplatin 25 / Etoposide 100, Neuroendocrine Prostate Cancer (PID1283)
Cisplatin 25 / Etoposide 60 / Irinotecan 90, Small Cell Lung Carcinoma (PID741)
Cisplatin 25 / Etoposide 80, Lung Carcinoma, Small Cell (PID216)
Cisplatin 25 / Gemcitabine 1000, Bile Duct Carcinoma (PID577)
Cisplatin 25 / Gemcitabine 600, Pancreatic Cancer (PID476)
Cisplatin 30 / Radiation, Head and Neck Tumors, adjuvant (PID1240)
Cisplatin 30, Tumor, Various Organs (PID2371)
Cisplatin 35 / Gemcitabine 1000, Ovarian Carcinoma (PID2190)
Cisplatin 40 / Doxorubicin 60, Thyroid Cancer (PID2140)
Cisplatin 40 / Folinic Acid 400 / Fluorouracil 1000, Anal Carcinoma (PID1978)
Cisplatin 40 / Radiation, Head and Neck Tumors (PID1637)
Cisplatin 40 / Radiation, Squamous Cell Carcinoma of the Skin (PID2162)
Cisplatin 40 / Radiation, Salivary Gland Tumor (PID1699)
Cisplatin 40 / Radiatio, Vulvar Carcinoma (PID2116)
Cisplatin 40 / Radiation, Cervical Cancer Adjuvant (PID540)
Cisplatin 50 / Etoposide 100 / Radiation, Non-Small Cell Lung Cancer, Neoadjuvant, Cycle 4 (PID619)
Cisplatin 50 / Etoposide 100, Adrenocortical Carcinoma (PID1369)
Cisplatin 50 / Etoposide 50 / Radiation, Non-Small Cell Lung Cancer (PID252)
Cisplatin 50 / Etoposide 50 / Radiation, Non-Small Cell Lung Cancer, Variant 1 (PID858)
Cisplatin 50 / Radiation, Endometrial Cancer adjuvant, Part A (PID922)
Cisplatin 60 / Etoposide 120 / Radiation, Small Cell Lung Carcinoma, Small Cell (PID264)
Cisplatin 60 / Etoposide 120, Lung Carcinoma, Small Cell (PID217)
Cisplatin 60 / Etoposide 150, Non-Small Cell Lung Cancer, Neoadjuvant, Cycle 1-3 (PID620)
Cisplatin 60 / Irinotecan 60, gastroenteral and pancreatic neuroendocrine carcinoma (PID2180)
Cisplatin 70 / Fluorouracil 700 / Radiation, Esophageal Cancer (PID1569)
Cisplatin 75 / Etoposide (100/200), Small Cell Lung Cancer (PID2558)
Cisplatin 75 / Etoposide 100 / Radiation, Small Cell Lung Carcinoma, Small Cell (PID1254)
Cisplatin 75 / Etoposide 100, Carcinoma of Unknown Primary (PID1186)
Cisplatin 75 / Etoposide 100, Small Cell Lung Carcinoma (PID2266)
Cisplatin 75 / Fluorouracil 1000 / Radiation, Esophageal Cancer (PID281)
Cisplatin 75 / Gemcitabine 1250, Carcinoma in Occult Primary (PID1187)
Cisplatin 75 / Gemcitabine 1250, Breast Cancer (PID763)
Cisplatin 75 / Tegafur 25 - Tegafur 25, Adenocarcinoma Esophagogastric Junction and Stomach, maintenance. (PID1106)
Cisplatin 75 / Tegafur 25, adenocarcinoma esophagogastric junction and stomach (PID202)
Cisplatin 80 / Etoposide 100 / Radiation, Small Cell Lung Carcinoma, Small Cell (PID265)
Cisplatin 80 / Etoposide 100 / Radiation, Small Cell Lung Cancer, Part A (PID266)
Cisplatin 80 / Etoposide 100, gastroenteral and pancreatic neuroendocrine carcinoma (PID2174)
Cisplatin 80 / Etoposide 100, Lung Carcinoma, Small Cell (PID214)
Cisplatin 80 / Etoposide 120, Lung Carcinoma, Small Cell (PID211)
Cisplatin 80 / Etoposide 80, Lung Carcinoma, Small Cell (PID215)
Cisplatin 80 / Fluorouracil 1000, Nasopharyngeal Carcinoma, Part B (PID1707)
Cisplatin 80 / Gemcitabine 1250 / Bevacizumab 7.5, Non-Small Cell Lung Cancer (PID770)
Cladribine 0.1, Langerhans Cell Histiocytosis (PID671)
Cladribine 0.12, Hairy Cell Leukemia (PID862)
Cladribine 0.14, Hairy Cell Leukemia (PID536)
Cladribine 0.14, systemic mastocytosis (PID1680)
Cladribine 0.14, Systemic Mastocytosis, Variant 1 (PID2332)
Cladribine 0.15 / Rituximab 375, classic Hairy Cell Leukemia and variants (PID864)
Cladribine 5 / Cytarabine 2000 / Idarubicin 12 / Filgrastim 300, Acute Myeloid Leukemia, Induction (PID2220)
Cladribine 5 / Cytarabine 2000 / Idarubicin 12 / Filgrastim 300, Acute Myeloid Leukemia, consolidation (PID2221)
Cladribine 5 / Cytarabine 2000 / Idarubicin 8, Acute Myeloid Leukemia (PID2209)
Cladribine 5 / Cytarabine 2000 / Mitoxantrone 10 / Filgrastim 300, Acute Myeloid Leukemia (PID2203)
Cladribine 5 / Cytarabine 2000, Acute Myeloid Leukemia (PID2204)
Cladribine 5 / Daunorubicin 60 / Cytarabine 200, Acute Myeloid Leukemia (PID2436)
Cladribine 5.6 followed by Rituximab 375, Hairy Cell Leukemia, Part A (PID865)
Cladribine 5.6 followed by Rituximab 375, Hairy Cell Leukemia, Part B (PID866)
CLAEG - Cladribine 0.2 / Etoposide 60 / Cytarabine 1500, T- Acute Lymphoblastic Leukaemia (PID1907)
CLAG - Cladribine 5 / Cytarabine 2000 / Filgrastim 300, AML (PID859)
Clodronic Acid (1040/520), Breast Cancer, Adjuvant (PID944)
Clodronic Acid 1040/520, Bone Metastases (PID945)
Clofarabin 10 / Cyclophosphamide 600, B/T-Acute Lymphoblastic Leukemia (PID2269)
Clofarabin 40, B/T-Acute Lymphoblastic Leukemia (PID2270)
CMF - Cyclophosphamide 100 / Methotrexate 40 / 5-fluorouracil 600, Breast Cancer (PID1153)
CMF - Cyclophosphamide 100 / Methotrexate 40 / Fluorouracil 600, Breast Cancer, adjuvant, variant 1 (PID1540)
CMF - Cyclophosphamide 600 / Methotrexate 40 / Fluorouracil 600, Breast Ca, adjuvant (PID100)
Cobimetinib 60, Langerhans Cell Histiocytosis (PID1996)
CODE - Cisplatin 25 / Doxorubicin 40 / Etoposide 80 / Vincristine 1, Thymoma (PID1843)
COMP - Cyclophosphamide 750 / Doxorubicin Liposomal 50 / Vincristine 2 / Prednisolone 100, T-cell Lymphoma (PID469)
Crizanlizumab 5, Sickle Cell Disease, Cycle 1 (PID1728)
Crizanlizumab 5, Sickle Cell Disease, Cycle 2+ (PID1729)
Crizotinib 250, diffuse large B-non-Hodgkin Lymphoma (PID2403)
Crizotinib 250, Non-Small Cell Lung Cancer (ALK+), First Line (PID807)
Crizotinib 250, Non-Small Cell Lung Cancer (ALK+), Second Line (PID198)
Crizotinib 250, Non-Small Cell Lung Cancer (METex14+) (PID1984)
Crizotinib 250, Non-Small Cell Lung Cancer (ROS1+) (PID806)
Crizotinib 250, Soft Tissue Sarcoma (PID2047)
CVD - Cyclophosphamide 750 / Vincristine 2 / Dacarbazine 600, Pheochromocytoma / Paraganglioma (PID2480)
Cyclophosphamide 1000 / Doxorubicin 45 / Etoposide 50, Small Cell Lung Carcinoma (PID260)
Cyclophosphamide 1000 / Doxorubicin 50 / Vincristine2, Small Cell Lung Carcinoma, Small Cell (PID224)
Cyclophosphamide 1000 / Etoposide (50/100) / Vincristine 2, Lung Carcinoma, Small Cell (PID225)
Cyclophosphamide 150, Ovarian Carcinoma (PID2192)
Cyclophosphamide 200 / Prednisolone 60, Pre-phase, Burkitt's lymphoma (PID2214)
Cyclophosphamide 2000 / Vincristine 2, Small Cell Lung Carcinoma, Small Cell (PID226)
Cyclophosphamide 2000, Breast Cancer, adjuvant, dose-dense (PID401)
Cyclophosphamide 50 / Methotrexate 2.5, Metastatic Breast Cancer (PID83)
Cyclophosphamide 50, Autoimmune Hemolytic Anemia, warm type (PID2016)
Cyclophosphamide 500 / Lenalidomide 25 / Dexamethasone 40, Multiple Myeloma (PID2264)
Cyclophosphamide 500 / Thalidomide 100 / Dexamethasone 40, Multiple Myeloma (PID2532)
Cyclophosphamide 500 / Thalidomide 50 / Dexamethasone 20, Multiple Myeloma (PID2533)
Cyclophosphamide 600 / Doxorubicin Liposomal 60, Breast Cancer (PID1686)
Cyclophosphamide 600 / Doxorubicin Liposomal 75, Breast Cancer (PID386)
Cyclophosphamide 600, Breast Cancer, adjuvant, dose-dense (PID1143)
Cyclophosphamide 750 / Doxorubicin 50 / Prednisolone 100 / Brentuximab Vedotin 1.8, T-cell Lymphoma (PID1204)
Cytarabine 100, Langerhans Cell Histiocytosis (PID1666)
Cytarabine 1000, Acute Myeloid Leukemia, consolidation, over 60 years of age (PID601)
Cytarabine 1500 / Mitoxantrone 10, Acute Myeloid Leukemia (PID2208)
Cytarabine 1500, Acute Myeloid Leukemia, Consolidation (PID2574)
Cytarabine 20 / Glasdegib 100, Acute Myeloid Leukemia and Myelodysplastic Syndrome (PID1674)
Cytarabine 20, Acute Myeloid Leukemia (PID833)
Cytarabine 2000 / Etoposide 5, CNS Lymphoma, cycle 6 (PID1866)
Cytarabine 3000 / Midostaurin 50, Acute Myeloid Leukemia, consolidation (PID1080)